Publications

NF-ºB as a target for pancreatic cancer therapy.  (2012)

Authors:
C. Carbone;D. Melisi
Title:
NF-ºB as a target for pancreatic cancer therapy.
Year:
2012
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Format:
A Stampa
Referee:
No
Name of journal:
EXPERT OPINION ON THERAPEUTIC TARGETS
ISSN of journal:
1472-8222
Page numbers:
1-10
Code PMID:
22443181
Keyword:
NFkB, TAK1
Short description of contents:
Introduction: Pancreatic cancer is the fourth leading cause of adult cancer mortality in the USA. It represents one of the greatest challenges in cancer treatment. The NF-ºB transcriptional factors are constitutively activated in the majority of pancreatic cancers and are involved in the regulation of numerous aspects of tumor development and progression. NF-ºB and the signaling cascades that regulate its activity have thus become attractive targets for novel therapeutic approaches for pancreatic cancer. Areas covered: This review describes and discusses the most important advances in the comprehension of the complex molecular biology of NF-ºB, as well as the development of novel NF-ºB-targeting strategies for the treatment of pancreatic cancer. Expert opinion: Although the inhibition of NF-ºB, especially when combined with more classic chemotherapeutic drugs, could be a promising therapeutic strategy, direct targeting NF-ºB still faces important challenges. In the future, targeting nonredundant cytosolic mediators of the activation of NF-ºB - such as TNF receptor associated factor family member-associated NF-ºB activator -binding kinase 1 (TBK1) and TGF-beta activated kinase 1 (TAK1) - could represent a better approach to inhibit key processes in pancreatic tumor cells and make a difference for this devastating disease.
Web page:
http://dx.doi.org/10.1517/14728222.2011.645806
Product ID:
66728
Handle IRIS:
11562/393944
Deposited On:
March 27, 2012
Last Modified:
November 2, 2016
Bibliographic citation:
C. Carbone;D. Melisi, NF-ºB as a target for pancreatic cancer therapy. «EXPERT OPINION ON THERAPEUTIC TARGETS»2012pp. 1-10

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

Related projects
Title Department Managers
Mechanisms of resistance to chemoterapeutic and antiangiogenic drugs as novel targets for pancreatic cancer therapy Department Medicina Davide Melisi
<<back

Activities

Research facilities